



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

December 2018





HIV/AIDS Drug Treatment Program

Monthly Report

© 2019 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

December 2018

N = 7358



Health Authority	Male	Female	All
FRASER	1422	427	1849
INTERIOR	392	98	490
NORTHERN	124	74	198
VANCOUVER COASTAL	3423	453	3876
VANCOUVER ISLAND	760	154	914
	6121	1206	7327
		Unknown/not stated:	31
		Total:	7358

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (December 2013 - December 2018)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (December 2013 - December 2018)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (December 2013 - December 2018)






1.5 BC-CfE Enrollment: New Antiretroviral Participants
(December 2013 - December 2018)






1.6 Percent Distribution of Active Participants by CD4 Count (December 2013 - December 2018)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(December 2013 - December 2018)






1.8 Active and Inactive Participants (December 2013 - December 2018)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (December 2013 - December 2018)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (December 2013 - December 2018)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(December 2013 - December 2018)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (December 2013 - December 2018)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(December 2013 - December 2018)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (December 2013 - December 2018)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(December 2013 - December 2018)





1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (December 2013 - December 2018)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(December 2013 - December 2018)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes






1.18 Baseline CD4 for Antiretroviral First Starts
(December 2013 - December 2018)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(December 2013 - December 2018)**





1.20 Cumulative Resistance Testing Results by Resistance Category (December 2013 - December 2018)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (December 2013 - December 2018)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2018
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	26	5	0	5	5	700	5	<40	3
1988	28	7	0	7	7	490	7	<40	3
1989	25	55	1	56	47	490	53	<40	3
1990	24	56	1	57	51	520	56	<40	3
1991	25	38	3	41	31	600	41	<40	3
1992	24	64	6	70	53	560	66	<40	3
1993	23	138	15	153	142	540	151	<40	3
1994	22	79	13	92	81	570	90	<40	3
1995	22	129	23	152	122	510	143	<40	3
1996	20	360	56	416	356	590	401	<40	3
1997	18	296	34	330	292	650	318	<40	3
1998	17	204	43	247	210	565	230	<40	3
1999	17	168	41	209	179	590	196	<40	3
2000	17	127	33	160	141	590	154	<40	3
2001	17	123	31	154	126	605	141	<40	3
2002	16	127	24	151	120	605	139	<40	3
2003	15	161	29	190	159	620	182	<40	3
2004	14	172	40	212	172	610	197	<40	3
2005	13	194	46	240	207	630	221	<40	3
2006	12	199	40	239	197	610	225	<40	3
2007	11	254	52	306	256	605	290	<40	3
2008	10	292	65	357	298	620	342	<40	3
2009	9	327	74	401	335	660	375	<40	3
2010	8	292	68	360	302	660	333	<40	3
2011	7	336	74	410	350	680	382	<40	3
2012	6	285	64	349	301	700	336	<40	3
2013	5	285	70	355	298	670	337	<40	3
2014	4	293	54	347	276	702	327	<40	3
2015	3	290	47	337	285	650	320	<40	3
2016	2	291	56	347	287	640	320	<40	3
2017	2	244	43	287	241	640	270	<40	3
2018	0	243	59	302	270	560	292	<40	3
Total:		6134	1205	7339					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2017	7182	747	2326	<40	2077	590
FEB-2017	7134	754	1914	<40	1740	590
MAR-2017	7186	744	2204	<40	2018	600
APR-2017	7178	746	1966	<40	1770	590
MAY-2017	7224	744	2275	<40	2057	590
JUN-2017	7245	751	2120	<40	1953	596
JUL-2017	7241	753	1965	<40	1789	580
AUG-2017	7266	756	2106	<40	1884	590
SEP-2017	7222	761	2042	<40	1837	610
OCT-2017	7244	769	2187	<40	1938	610
NOV-2017	7240	766	2073	<40	1872	610
DEC-2017	7227	775	1740	<40	1537	610
JAN-2018	7293	755	2386	<40	2104	610
FEB-2018	7256	765	1904	<40	1742	610
MAR-2018	7278	774	2049	<40	1826	618
APR-2018	7264	778	2082	<40	1841	620
MAY-2018	7287	780	2149	<40	1925	600
JUN-2018	7293	794	2008	<40	1788	610
JUL-2018	7299	796	2038	<40	1810	600
AUG-2018	7298	801	2093	<40	1864	613
SEP-2018	7253	805	2015	<40	1759	630
OCT-2018	7346	784	2168	<40	1906	610
NOV-2018	7355	789	2093	<40	1751	630
DEC-2018	7358	801	1748	<40	1446	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2017	1402	3157	88	140	80	417
FEB-2017	1455	2851	80	1874	70	400
MAR-2017	1408	3137	99	635	89	380
APR-2017	1424	3090	94	545	85	420
MAY-2017	1395	3282	85	180	75	420
JUN-2017	1385	3366	76	197	69	480
JUL-2017	1405	3254	67	436	60	500
AUG-2017	1397	3352	78	160	68	495
SEP-2017	1451	3065	74	323	66	415
OCT-2017	1421	3271	91	218	80	470
NOV-2017	1440	3197	80	133	69	370
DEC-2017	1470	3055	60	53	51	380
JAN-2018	1421	3363	78	872	71	380
FEB-2018	1465	3136	79	1036	65	440
MAR-2018	1451	3234	75	59	70	485
APR-2018	1469	3173	71	808	62	484
MAY-2018	1452	3290	91	<40	82	455
JUN-2018	1459	3283	68	2980	64	440
JUL-2018	1462	3290	68	<40	53	570
AUG-2018	1497	3179	63	56	55	494
SEP-2018	1543	2987	89	181	82	415
OCT-2018	1472	3338	80	52	69	350
NOV-2018	1475	3338	80	80	67	480
DEC-2018	1486	3317	56	259	45	450

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2017	7140	1402	21	21	141	142	-6	12877
FEB-2017	7102	1455	10	24	136	182	-38	12911
MAR-2017	7147	1408	17	19	189	139	45	12937
APR-2017	7139	1424	12	20	143	151	-8	12969
MAY-2017	7194	1395	7	22	170	126	55	13003
JUN-2017	7209	1385	10	24	151	138	15	13033
JUL-2017	7200	1405	8	14	134	142	-9	13052
AUG-2017	7227	1397	10	25	156	136	27	13082
SEP-2017	7181	1451	12	16	137	177	-46	13111
OCT-2017	7211	1421	7	6	184	147	30	13124
NOV-2017	7204	1440	16	19	142	148	-7	13159
DEC-2017	7196	1470	5	18	158	174	-8	13190
JAN-2018	7251	1421	13	12	192	126	55	13219
FEB-2018	7220	1465	11	27	123	167	-31	13256
MAR-2018	7238	1451	17	21	152	134	18	13283
APR-2018	7230	1469	13	15	153	159	-8	13305
MAY-2018	7258	1452	9	12	171	144	28	13330
JUN-2018	7257	1459	13	16	149	150	-1	13352
JUL-2018	7256	1462	13	14	158	152	-1	13378
AUG-2018	7264	1497	9	27	155	162	8	13417
SEP-2018	7219	1543	16	15	154	193	-45	13443
OCT-2018	7316	1472	8	19	217	127	97	13479
NOV-2018	7335	1475	5	9	175	159	19	13505
DEC-2018	7339	1486	11	20	144	149	4	13531

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2017	61	6615	443	63	7182	0.85%	92.11%	6.17%	0.88%	100.00%
FEB-2017	60	6579	440	55	7134	0.84%	92.22%	6.17%	0.77%	100.00%
MAR-2017	60	6629	439	58	7186	0.83%	92.25%	6.11%	0.81%	100.00%
APR-2017	58	6633	428	59	7178	0.81%	92.41%	5.96%	0.82%	100.00%
MAY-2017	62	6665	438	59	7224	0.86%	92.26%	6.06%	0.82%	100.00%
JUN-2017	57	6691	438	59	7245	0.79%	92.35%	6.05%	0.81%	100.00%
JUL-2017	61	6685	433	62	7241	0.84%	92.32%	5.98%	0.86%	100.00%
AUG-2017	61	6696	448	61	7266	0.84%	92.16%	6.17%	0.84%	100.00%
SEP-2017	57	6677	431	57	7222	0.79%	92.45%	5.97%	0.79%	100.00%
OCT-2017	58	6691	438	57	7244	0.80%	92.37%	6.05%	0.79%	100.00%
NOV-2017	59	6680	445	56	7240	0.81%	92.27%	6.15%	0.77%	100.00%
DEC-2017	58	6666	447	56	7227	0.80%	92.24%	6.19%	0.77%	100.00%
JAN-2018	58	6729	451	55	7293	0.80%	92.27%	6.18%	0.75%	100.00%
FEB-2018	62	6684	451	59	7256	0.85%	92.12%	6.22%	0.81%	100.00%
MAR-2018	63	6707	453	56	7279	0.87%	92.14%	6.22%	0.77%	100.00%
APR-2018	58	6699	449	58	7264	0.80%	92.22%	6.18%	0.80%	100.00%
MAY-2018	64	6711	455	58	7288	0.88%	92.08%	6.24%	0.80%	100.00%
JUN-2018	61	6725	449	58	7293	0.84%	92.21%	6.16%	0.80%	100.00%
JUL-2018	53	6730	461	55	7299	0.73%	92.20%	6.32%	0.75%	100.00%
AUG-2018	54	6734	454	56	7298	0.74%	92.27%	6.22%	0.77%	100.00%
SEP-2018	51	6685	458	59	7253	0.70%	92.17%	6.31%	0.81%	100.00%
OCT-2018	53	6764	475	54	7346	0.72%	92.08%	6.47%	0.74%	100.00%
NOV-2018	54	6774	477	50	7355	0.73%	92.10%	6.49%	0.68%	100.00%
DEC-2018	53	6778	478	49	7358	0.72%	92.12%	6.50%	0.67%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	13 41%	3068 44%	13 41%	2772 40%	0 0%	75 1%	0 0%	5 0%	0 0%	6 0%	0 0%	46 1%	19 59%	4051 58%
FEB-2017	12 35%	3074 44%	10 29%	2783 40%	1 3%	71 1%	0 0%	5 0%	0 0%	6 0%	0 0%	50 1%	22 65%	3982 58%
MAR-2017	7 27%	3105 45%	7 27%	2824 41%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	0 0%	78 1%	19 73%	4000 57%
APR-2017	13 41%	3114 45%	12 38%	2834 41%	1 3%	68 1%	0 0%	6 0%	0 0%	6 0%	0 0%	96 1%	19 59%	3962 57%
MAY-2017	9 26%	3159 45%	9 26%	2881 41%	0 0%	73 1%	0 0%	6 0%	0 0%	5 0%	1 3%	119 2%	24 71%	3930 56%
JUN-2017	6 20%	3169 45%	6 20%	2902 41%	0 0%	71 1%	0 0%	6 0%	0 0%	5 0%	2 7%	143 2%	22 73%	3898 55%
JUL-2017	7 37%	3198 46%	7 37%	2928 42%	0 0%	72 1%	0 0%	6 0%	0 0%	5 0%	0 0%	161 2%	12 63%	3861 55%
AUG-2017	6 20%	3224 46%	4 13%	2958 42%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	2 7%	171 2%	23 77%	3838 54%
SEP-2017	10 34%	3213 46%	10 34%	2950 42%	0 0%	66 1%	0 0%	5 0%	0 0%	4 0%	3 10%	207 3%	16 55%	3775 54%
OCT-2017	5 38%	3241 46%	5 38%	2983 42%	0 0%	65 1%	0 0%	4 0%	0 0%	4 0%	2 15%	245 3%	6 46%	3715 53%
NOV-2017	9 26%	3280 47%	8 23%	3024 43%	0 0%	65 1%	0 0%	5 0%	0 0%	4 0%	1 3%	265 4%	25 71%	3661 52%
DEC-2017	10 32%	3286 47%	10 32%	3032 43%	0 0%	64 1%	0 0%	5 0%	0 0%	4 0%	1 3%	272 4%	22 71%	3612 52%
JAN-2018	10 36%	3320 47%	9 32%	3076 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3635 51%
FEB-2018	13 35%	3320 47%	12 32%	3078 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3586 51%
MAR-2018	10 37%	3339 47%	10 37%	3103 44%	0 0%	60 1%	0 0%	4 0%	0 0%	4 0%	0 0%	311 4%	17 63%	3567 50%
APR-2018	5 23%	3347 47%	5 23%	3115 44%	0 0%	56 1%	0 0%	3 0%	0 0%	4 0%	2 9%	333 5%	15 68%	3540 50%
MAY-2018	9 39%	3355 47%	8 35%	3129 44%	1 4%	57 1%	0 0%	5 0%	0 0%	4 0%	1 4%	351 5%	13 57%	3516 50%
JUN-2018	6 30%	3373 48%	6 30%	3149 44%	0 0%	54 1%	0 0%	5 0%	0 0%	3 0%	1 5%	380 5%	13 65%	3486 49%
JUL-2018	7 28%	3401 48%	7 28%	3178 45%	0 0%	51 1%	0 0%	5 0%	0 0%	3 0%	4 16%	398 6%	14 56%	3454 49%
AUG-2018	13 33%	3398 48%	14 36%	3186 45%	0 0%	50 1%	0 0%	4 0%	0 0%	3 0%	2 5%	415 6%	23 59%	3418 48%
SEP-2018	4 15%	3380 48%	3 12%	3166 45%	1 4%	47 1%	0 0%	4 0%	0 0%	2 0%	4 15%	446 6%	18 69%	3375 48%
OCT-2018	11 31%	3422 48%	9 26%	3209 45%	1 3%	49 1%	0 0%	3 0%	0 0%	2 0%	0 0%	478 7%	25 71%	3387 47%
NOV-2018	9 35%	3434 48%	8 31%	3221 45%	0 0%	47 1%	0 0%	4 0%	0 0%	2 0%	1 4%	491 7%	17 65%	3359 47%
DEC-2018	8 31%	3446 48%	8 31%	3235 45%	0 0%	45 1%	0 0%	4 0%	0 0%	1 0%	2 8%	502 7%	16 62%	3351 47%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2017	19	59%	3828	55%
FEB-2017	22	65%	3771	55%
MAR-2017	19	73%	3803	55%
APR-2017	19	59%	3791	55%
MAY-2017	25	74%	3795	54%
JUN-2017	24	80%	3797	54%
JUL-2017	12	63%	3770	54%
AUG-2017	24	80%	3767	53%
SEP-2017	19	66%	3740	53%
OCT-2017	7	54%	3731	53%
NOV-2017	26	74%	3693	53%
DEC-2017	21	68%	3665	52%
JAN-2018	18	64%	3711	52%
FEB-2018	24	65%	3680	52%
MAR-2018	17	63%	3673	52%
APR-2018	17	77%	3662	52%
MAY-2018	14	61%	3662	52%
JUN-2018	14	70%	3663	52%
JUL-2018	18	72%	3656	52%
AUG-2018	25	64%	3651	52%
SEP-2018	22	85%	3634	52%
OCT-2018	24	69%	3686	52%
NOV-2018	17	65%	3674	51%
DEC-2018	18	69%	3669	51%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	0 0%	9 0%	2 14%	1558 50%	12 86%	1313 42%	0 0%	247 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
FEB-2017	0 0%	9 0%	3 19%	1518 49%	12 75%	1307 43%	1 6%	236 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
MAR-2017	0 0%	8 0%	1 8%	1513 49%	11 92%	1329 43%	0 0%	232 8%	0 0%	2 0%	0 0%	1 0%	0 0%	12 0%
APR-2017	0 0%	8 0%	0 0%	1484 49%	5 71%	1318 43%	2 29%	231 8%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2017	0 0%	9 0%	0 0%	1462 48%	14 100%	1350 44%	0 0%	227 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUN-2017	0 0%	9 0%	2 18%	1453 48%	9 82%	1359 45%	0 0%	221 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUL-2017	0 0%	9 0%	0 0%	1439 47%	6 100%	1359 45%	0 0%	218 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
AUG-2017	0 0%	9 0%	1 5%	1417 47%	21 95%	1396 46%	0 0%	216 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
SEP-2017	0 0%	9 0%	0 0%	1388 46%	8 100%	1389 46%	0 0%	210 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
OCT-2017	0 0%	8 0%	0 0%	1364 46%	6 100%	1396 47%	0 0%	207 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
NOV-2017	0 0%	8 0%	1 8%	1324 45%	10 83%	1392 48%	1 8%	205 7%	0 0%	3 0%	0 0%	1 0%	0 0%	10 0%
DEC-2017	0 0%	7 0%	1 7%	1295 45%	14 93%	1397 48%	0 0%	197 7%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JAN-2018	0 0%	8 0%	3 30%	1318 45%	7 70%	1418 48%	0 0%	196 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1258 44%	15 100%	1422 49%	0 0%	190 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1247 43%	10 91%	1439 50%	0 0%	188 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1223 43%	11 100%	1437 50%	0 0%	182 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1210 43%	5 100%	1443 51%	0 0%	181 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JUN-2018	0 0%	7 0%	1 8%	1191 42%	11 92%	1435 51%	0 0%	177 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
JUL-2018	0 0%	7 0%	2 20%	1171 42%	7 70%	1444 52%	1 10%	170 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
AUG-2018	0 0%	7 0%	5 31%	1157 42%	11 69%	1426 52%	0 0%	166 6%	0 0%	1 0%	0 0%	1 0%	0 0%	8 0%
SEP-2018	0 0%	7 0%	1 14%	1134 42%	6 86%	1410 52%	0 0%	160 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
OCT-2018	0 0%	7 0%	3 17%	1123 41%	15 83%	1450 53%	0 0%	155 6%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
NOV-2018	0 0%	6 0%	1 14%	1116 41%	6 86%	1462 53%	0 0%	148 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
DEC-2018	0 0%	5 0%	1 11%	1102 41%	7 78%	1464 54%	1 11%	146 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2017	0	0%	1	0%
FEB-2017	0	0%	1	0%
MAR-2017	0	0%	1	0%
APR-2017	0	0%	1	0%
MAY-2017	0	0%	1	0%
JUN-2017	0	0%	1	0%
JUL-2017	0	0%	1	0%
AUG-2017	0	0%	1	0%
SEP-2017	0	0%	1	0%
OCT-2017	0	0%	1	0%
NOV-2017	0	0%	1	0%
DEC-2017	0	0%	1	0%
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%
JUN-2018	0	0%	1	0%
JUL-2018	0	0%	1	0%
AUG-2018	0	0%	1	0%
SEP-2018	0	0%	1	0%
OCT-2018	0	0%	1	0%
NOV-2018	0	0%	1	0%
DEC-2018	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2017	4 80%	928 41%	0 0%	292 13%	1 20%	799 35%	0 0%	269 12%
FEB-2017	4 80%	907 40%	0 0%	280 12%	0 0%	791 35%	1 20%	266 12%
MAR-2017	1 50%	897 40%	0 0%	279 13%	0 0%	790 35%	1 50%	265 12%
APR-2017	4 44%	888 40%	0 0%	273 12%	1 11%	787 36%	4 44%	271 12%
MAY-2017	3 75%	877 40%	0 0%	274 12%	0 0%	783 35%	1 25%	279 13%
JUN-2017	3 100%	853 39%	0 0%	270 12%	0 0%	782 36%	0 0%	288 13%
JUL-2017	2 100%	838 39%	0 0%	264 12%	0 0%	779 36%	0 0%	283 13%
AUG-2017	1 100%	821 38%	0 0%	268 12%	0 0%	777 36%	0 0%	285 13%
SEP-2017	4 50%	808 38%	0 0%	264 12%	1 13%	774 36%	3 38%	296 14%
OCT-2017	1 100%	802 38%	0 0%	267 13%	0 0%	768 36%	0 0%	299 14%
NOV-2017	5 71%	800 38%	0 0%	269 13%	0 0%	767 36%	2 29%	300 14%
DEC-2017	3 75%	793 38%	0 0%	263 12%	0 0%	758 36%	1 25%	301 14%
JAN-2018	3 50%	779 37%	1 17%	263 13%	2 33%	757 36%	0 0%	302 14%
FEB-2018	3 75%	771 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	1 33%	758 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	1 50%	745 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%
JUN-2018	1 50%	721 36%	0 0%	248 12%	0 0%	725 36%	1 50%	314 16%
JUL-2018	3 60%	723 36%	0 0%	243 12%	0 0%	717 36%	2 40%	314 16%
AUG-2018	2 100%	715 36%	0 0%	238 12%	0 0%	716 36%	0 0%	308 16%
SEP-2018	6 100%	707 36%	0 0%	236 12%	0 0%	712 36%	0 0%	311 16%
OCT-2018	3 60%	697 36%	0 0%	234 12%	0 0%	710 36%	2 40%	324 17%
NOV-2018	8 80%	688 35%	0 0%	230 12%	0 0%	700 36%	2 20%	323 17%
DEC-2018	1 100%	682 36%	0 0%	225 12%	0 0%	696 36%	0 0%	320 17%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide													
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All												
JAN-2017	0	0%	0	0%	13	81%	1518	53%	3	19%	587	20%	0	0%	52	2%	0	0%	756	26%	0	0%	1	0%
FEB-2017	0	0%	0	0%	14	78%	1560	54%	4	22%	588	20%	0	0%	48	2%	0	0%	732	25%	0	0%	1	0%
MAR-2017	0	0%	0	0%	13	87%	1620	55%	2	13%	601	20%	0	0%	49	2%	0	0%	732	25%	0	0%	1	0%
APR-2017	0	0%	0	0%	14	78%	1655	55%	4	22%	596	20%	0	0%	50	2%	0	0%	722	24%	0	0%	1	0%
MAY-2017	0	0%	0	0%	19	86%	1726	57%	3	14%	602	20%	0	0%	47	2%	0	0%	715	23%	0	0%	1	0%
JUN-2017	0	0%	0	0%	12	75%	1757	57%	3	19%	596	19%	0	0%	49	2%	1	6%	713	23%	0	0%	1	0%
JUL-2017	0	0%	0	0%	8	73%	1791	58%	3	27%	592	19%	0	0%	48	2%	0	0%	705	23%	0	0%	1	0%
AUG-2017	0	0%	0	0%	13	72%	1824	58%	4	22%	596	19%	0	0%	49	2%	1	6%	707	22%	0	0%	1	0%
SEP-2017	0	0%	0	0%	10	71%	1833	58%	4	29%	600	19%	0	0%	50	2%	0	0%	700	22%	0	0%	1	0%
OCT-2017	0	0%	0	0%	8	89%	1879	59%	1	11%	608	19%	0	0%	48	1%	0	0%	708	22%	0	0%	0	0%
NOV-2017	0	0%	0	0%	14	67%	1939	60%	5	24%	611	19%	0	0%	49	2%	2	10%	701	22%	0	0%	0	0%
DEC-2017	0	0%	0	0%	11	69%	1958	60%	5	31%	603	18%	0	0%	48	1%	0	0%	689	21%	0	0%	0	0%
JAN-2018	0	0%	0	0%	9	47%	2006	60%	8	42%	631	19%	0	0%	46	1%	2	11%	688	21%	0	0%	0	0%
FEB-2018	0	0%	0	0%	16	70%	2027	60%	6	26%	642	19%	0	0%	45	1%	1	4%	676	20%	0	0%	0	0%
MAR-2018	0	0%	0	0%	14	100%	2061	61%	0	0%	645	19%	0	0%	43	1%	0	0%	674	20%	0	0%	0	0%
APR-2018	0	0%	0	0%	8	67%	2106	61%	4	33%	654	19%	0	0%	44	1%	0	0%	681	20%	0	0%	0	0%
MAY-2018	0	0%	0	0%	13	65%	2139	61%	4	20%	665	19%	1	5%	42	1%	3	15%	675	19%	0	0%	0	0%
JUN-2018	0	0%	0	0%	7	64%	2174	62%	3	27%	675	19%	0	0%	42	1%	1	9%	678	19%	0	0%	0	0%
JUL-2018	0	0%	0	0%	7	58%	2210	62%	4	33%	676	19%	0	0%	43	1%	1	8%	677	19%	0	0%	0	0%
AUG-2018	0	0%	0	0%	23	79%	2256	62%	5	17%	676	19%	0	0%	42	1%	1	3%	671	19%	0	0%	0	0%
SEP-2018	0	0%	9	0%	5	36%	2261	62%	9	64%	690	19%	0	0%	41	1%	0	0%	656	18%	0	0%	0	0%
OCT-2018	0	0%	17	0%	13	76%	2318	63%	4	24%	708	19%	0	0%	40	1%	0	0%	659	18%	0	0%	0	0%
NOV-2018	0	0%	17	0%	11	100%	2346	63%	0	0%	706	19%	0	0%	38	1%	0	0%	651	17%	0	0%	0	0%
DEC-2018	0	0%	17	0%	13	72%	2365	63%	5	28%	719	19%	0	0%	39	1%	0	0%	650	17%	0	0%	0	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2017	2155	30.01	1793	24.97	2135	29.73	139	1.94	63	0.88	897	12.49
FEB-2017	2125	29.79	1772	24.84	2165	30.35	133	1.86	55	0.77	884	12.39
MAR-2017	2133	29.68	1754	24.41	2223	30.94	134	1.86	58	0.81	884	12.30
APR-2017	2109	29.38	1744	24.30	2260	31.49	133	1.85	59	0.82	873	12.16
MAY-2017	2108	29.18	1737	24.04	2308	31.95	132	1.83	59	0.82	880	12.18
JUN-2017	2115	29.19	1719	23.73	2349	32.42	132	1.82	59	0.81	871	12.02
JUL-2017	2102	29.03	1694	23.39	2386	32.95	130	1.80	62	0.86	867	11.97
AUG-2017	2094	28.82	1687	23.22	2408	33.14	130	1.79	61	0.84	886	12.19
SEP-2017	2074	28.72	1676	23.21	2427	33.61	127	1.76	57	0.79	861	11.92
OCT-2017	2050	28.30	1674	23.11	2476	34.18	124	1.71	57	0.79	863	11.91
NOV-2017	2003	27.67	1668	23.04	2519	34.79	119	1.64	56	0.77	875	12.09
DEC-2017	1998	27.65	1660	22.97	2531	35.02	115	1.59	56	0.77	867	12.00
JAN-2018	2010	27.56	1645	22.56	2595	35.58	117	1.60	55	0.75	871	11.94
FEB-2018	1967	27.11	1630	22.46	2615	36.04	116	1.60	59	0.81	869	11.98
MAR-2018	1978	27.17	1616	22.20	2647	36.36	113	1.55	56	0.77	869	11.94
APR-2018	1937	26.67	1596	21.97	2698	37.14	114	1.57	58	0.80	861	11.85
MAY-2018	1931	26.50	1575	21.61	2738	37.57	114	1.56	58	0.80	872	11.96
JUN-2018	1912	26.22	1564	21.45	2790	38.26	113	1.55	58	0.80	856	11.74
JUL-2018	1888	25.87	1567	21.47	2820	38.64	110	1.51	55	0.75	859	11.77
AUG-2018	1866	25.57	1549	21.22	2865	39.26	111	1.52	56	0.77	851	11.66
SEP-2018	1832	25.26	1533	21.14	2878	39.68	109	1.50	59	0.81	842	11.61
OCT-2018	1855	25.25	1529	20.81	2946	40.10	104	1.42	54	0.74	858	11.68
NOV-2018	1846	25.10	1524	20.72	2971	40.39	106	1.44	50	0.68	858	11.67
DEC-2018	1839	24.99	1509	20.51	3002	40.80	103	1.40	49	0.67	856	11.63

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2017	21	3	2	3	6	6	390
FEB-2017	24	5	3	1	3	10	425
MAR-2017	19	5	3	5	2	2	220
APR-2017	20	1	2	6	5	5	350
MAY-2017	22	2	0	3	9	8	405
JUN-2017	24	6	2	5	3	7	230
JUL-2017	14	2	2	2	1	5	340
AUG-2017	25	4	0	4	3	12	510
SEP-2017	16	1	2	3	3	5	440
OCT-2017	6	2	0	0	2	2	435
NOV-2017	19	2	1	6	3	7	430
DEC-2017	18	2	2	4	4	5	390
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	21	4	1	5	4	6	325
APR-2018	15	0	0	5	3	5	480
MAY-2018	12	1	0	4	3	2	370
JUN-2018	16	3	5	1	1	6	237
JUL-2018	14	4	1	3	4	1	284
AUG-2018	27	2	2	6	4	13	450
SEP-2018	15	2	3	1	3	5	405
OCT-2018	19	0	1	2	5	10	525
NOV-2018	9	2	2	2	0	2	185
DEC-2018	20	2	0	5	5	8	433

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2017	11552	3372
FEB-2017	11577	3379
MAR-2017	11628	3428
APR-2017	11654	3443
MAY-2017	11695	3468
JUN-2017	11722	3482
JUL-2017	11753	3512
AUG-2017	11789	3539
SEP-2017	11816	3564
OCT-2017	11873	3618
NOV-2017	11884	3616
DEC-2017	11911	3622
JAN-2018	11969	3664
FEB-2018	11998	3678
MAR-2018	12026	3707
APR-2018	12056	3736
MAY-2018	12091	3761
JUN-2018	12103	3764
JUL-2018	12129	3788
AUG-2018	12143	3783
SEP-2018	12167	3806
OCT-2018	12188	3807
NOV-2018	12226	3827
DEC-2018	12231	3822

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
December 2018

N = 7358

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2018

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2018

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2018

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2018

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2018

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	5	5	*
	35-49	11	13	*
	50+	25	36	*
	Total HSDA:	41	54	28
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	70	93	51	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	362	485	270	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	14
	35-49	*	*	43
	50+	*	*	84
Total HSDA:	186	249	141	
Total HA:		659	881	490

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		659	881	490

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	522	702	392
Female	137	179	98

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	490	54	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	10
	5 years or more	7	5
	<5 years	16	13
	Total HSDA:	41	28
KOOTENAY BOUNDARY	10 years or more	44	31
	5 years or more	13	10
	<5 years	13	10
	Total HSDA:	70	51
OKANAGAN	10 years or more	222	159
	5 years or more	61	50
	<5 years	79	61
	Total HSDA:	362	270
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	103	72
	5 years or more	39	33
	<5 years	44	36
	Total HSDA:	186	141
Total HA:		659	490

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	387	272
5 years or more	120	98
<5 years	152	120
Total HA:	659	490

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	40	58	13	23
KOOTENAY BOUNDARY	68	119	22	43
OKANAGAN	210	795	61	282
THOMPSON/CARIBOO/SHUSWAP	126	487	36	133
Total:	444	1459	132	481

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	89

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		361	446
FRASER NORTH	0-19	10	10	*
	20-34	113	115	*
	35-49	346	382	*
	50+	528	839	*
	Total HSDA:		997	1346
FRASER SOUTH	0-19	7	7	5
	20-34	107	109	77
	35-49	346	395	288
	50+	514	756	437
	Total HSDA:		974	1267
Total HA:		2332	3059	1849

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	21	21	11
	20-34	250	256	175
	35-49	803	900	633
	50+	1258	1882	1030
Total HA:		2332	3059	1849

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1772	2348	1422
Female	560	711	427

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1849	51	620	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	196	148
	5 years or more	93	71
	<5 years	72	55
	Total HSDA:	361	274
FRASER NORTH	10 years or more	527	383
	5 years or more	258	206
	<5 years	212	179
	Total HSDA:	997	768
FRASER SOUTH	10 years or more	507	414
	5 years or more	227	185
	<5 years	240	208
	Total HSDA:	974	807
Total HA:		2332	1849

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1230	945
	5 years or more	578	462
	<5 years	524	442
Total HA:		2332	1849

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	137	484	37	68
FRASER NORTH	247	1537	56	249
FRASER SOUTH	210	1323	44	360
Total:	594	3344	137	677

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	196
FRASER NORTH	655
FRASER SOUTH	542
Total:	1393

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	18
	35-49	*	*	65
	50+	*	*	196
	Total HSDA:		330	475
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		168	217
VANCOUVER	0-19	36	39	7
	20-34	435	446	313
	35-49	1436	1620	1064
	50+	2737	4643	2083
	Total HSDA:	4644	6748	3467
Total HA:		5142	7440	3876

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	39	42	8
	20-34	486	498	348
	35-49	1562	1759	1165
	50+	3055	5141	2355
Total HA:		5142	7440	3876

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4520	6525	3423
Female	620	913	453

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3876	53	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	179	149
	5 years or more	83	70
	<5 years	68	60
	Total HSDA:	330	279
RICHMOND	10 years or more	87	64
	5 years or more	42	33
	<5 years	39	33
	Total HSDA:	168	130
VANCOUVER	10 years or more	2612	1865
	5 years or more	1191	911
	<5 years	841	691
	Never on ART	0	0
	Total HSDA:	4644	3467
Total HA:	5142	3876	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2878	2078
5 years or more	1316	1014
<5 years	948	784
Never on ART	0	0
Total HA:	5142	3876

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	165	483	51	174
RICHMOND	43	284	12	95
VANCOUVER	584	10654	194	5355
Total:	792	11421	257	5624

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	116

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		317	443
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		120	159
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		715	1011
Total HA:		1152	1613	914

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	103	109	*
	35-49	307	355	*
	50+	736	1143	*
Total HA:		1152	1613	914

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	948	1328	760
Female	204	285	154

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	914	54	530	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	167	133
	5 years or more	73	62
	<5 years	77	59
	Total HSDA:	317	254
NORTH VANCOUVER ISLAND	10 years or more	66	57
	5 years or more	31	23
	<5 years	23	20
	Total HSDA:	120	100
SOUTH VANCOUVER ISLAND	10 years or more	399	292
	5 years or more	158	132
	<5 years	158	136
	Total HSDA:	715	560
Total HA:		1152	914

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	632	482
	5 years or more	262	217
	<5 years	258	215
Total HA:		1152	914

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	191	834	75	192
NORTH VANCOUVER ISLAND	129	258	43	72
SOUTH VANCOUVER ISLAND	207	1739	46	559
Total:	527	2831	164	823

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	51
NORTH VANCOUVER ISLAND	35
SOUTH VANCOUVER ISLAND	105
Total:	191

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		39	47
NORTH WEST	0-19	*	*	0
	20-34	*	*	6
	35-49	*	*	15
	50+	*	*	29
	Total HSDA:		69	107
NORTHERN INTERIOR	0-19	5	5	*
	20-34	17	20	*
	35-49	72	88	*
	50+	84	141	*
	Total HSDA:		178	254
Total HA:		286	408	198

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	29	34	*
	35-49	110	145	*
	50+	140	222	*
Total HA:		286	408	198

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	175	253	124
Female	111	155	74

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	198	51	560	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	17	7
	5 years or more	14	7
	<5 years	8	6
	Total HSDA:	39	20
NORTH WEST	10 years or more	30	18
	5 years or more	27	23
	<5 years	12	9
	Total HSDA:	69	50
NORTHERN INTERIOR	10 years or more	70	49
	5 years or more	63	50
	<5 years	45	29
	Total HSDA:	178	128
Total HA:		286	198

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	117	74
	5 years or more	104	80
	<5 years	65	44
Total HA:		286	198

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	38	61	8	8
NORTH WEST	70	158	15	27
NORTHERN INTERIOR	104	444	15	181
Total:	212	663	38	216

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	19
NORTHERN INTERIOR	18
Total:	43

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	22	37	*
	THOMPSON/CARIBOO/SHUSWAP	26	44	*
	Total HA:	60	100	43
FRASER	FRASER EAST	41	51	32
	FRASER NORTH	54	90	45
	FRASER SOUTH	69	102	54
	Total HA:	164	243	131
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	48	23
	RICHMOND	12	17	8
	VANCOUVER	500	848	395
	Total HA:	537	913	426
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	79	41
	NORTH VANCOUVER ISLAND	15	24	13
	SOUTH VANCOUVER ISLAND	33	75	28
	Total HA:	99	178	82
NORTHERN	NORTH EAST	10	12	6
	NORTH WEST	32	61	24
	NORTHERN INTERIOR	61	98	47
	Total HA:	103	171	77
Total:		963	1605	759

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	601	1024	481
Female	362	581	278

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	759	51	510	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by





blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

